Roche RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Susvimo (ranibizumab injection). The regulatory body approved the drug Susvimo for the treatment of ...

Bayer BAYRY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR).

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Results of a phase IIb trial comparing UBX1325 to anti-VEGF therapy are expected later this year. A single intravitreal injection of UBX1325 (foselutoclax), a novel senolytic small molecule ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of ...

Biotechnology company Optigo Biotherapeutics received the People’s Choice Award at the 2025 Eyecelerator meeting for the ...